Immunohistochemical phenotype of fallopian tubes in patients with different grades of serous ovarian carcinoma

---

Original Article

Author Details : Tamar Dzotsenidze, Arsen Gvenetadze, Mariam Gachechiladze, George Burkadze, Shota Kepuladze*

Volume : 9, Issue : 4, Year : 2022

Article Page : 301-305

https://doi.org/10.18231/j.ijpo.2022.073

Suggest article by email

Get Permission

---

Abstract

During recent years, there is an accumulating evidence that high grade ovarian carcinoma is developed from the fallopian tube epithelial lesions. However, is not yet completely understood and still represents the subject of investigation. We investigated the immunohistochemical phenotype of matched fallopian tubes from the patients with different types and malignancy grades of ovarian carcinoma. Matched fallopian tubes from ovarian cancer patients were available in 260 cases, including mucinous borderline tumor (n=25), mucinous carcinoma (n=15), serous borderline tumor (n=90), low grade serous carcinoma (n=72) and high grade serous carcinoma (n=48). Immunohistochemical investigation included markers of proliferation (Ki67), apoptosis (Bcl2, p53), hormone receptors (ER, PR), epithelial differentiation (CK7), mesenchymal differentiation (vimentin, calretinin) and stem cells (CD44). The results indicate that the presence of fallopian tube carcinoma in situ is significantly correlated with the presence of high grade ovarian serous carcinoma (r=0.44, p<0>  

Keywords: High grade ovarian carcinoma, Fallopian tubes.

How to cite : Dzotsenidze T, Gvenetadze A, Gachechiladze M, Burkadze G, Kepuladze S, Immunohistochemical phenotype of fallopian tubes in patients with different grades of serous ovarian carcinoma. Indian J Pathol Oncol 2022;9(4):301-305

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.